DaShenLin Pharmaceutical Group Co., Ltd. Class A

DaShenLin Pharmaceutical Group Co., Ltd. Class A

SSSE:603233
20.82
CNY
+0.03
(+0.14%)
1.38EPS
14.47P/E
20.73BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 20.73B, placing it among publicly traded companies globally. Its enterprise value stands at 20.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap20.73B
Enterprise Value20.77B

Important Dates

DaShenLin Pharmaceutical Group Co., Ltd. Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A has 1.14B shares outstanding.

Shares Outstanding1.14B

Valuation Ratios

As of September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 14.47. The price-to-sales ratio is 0.72, and the price-to-book ratio stands at 2.73.

PE Ratio14.47
PS Ratio0.72
PB Ratio2.73
P/TBV Ratio10.63

Enterprise Valuation

As of September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A trades at an EV/EBITDA multiple of 9.79 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.79 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 20.77B versus a market cap of 20.73B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.72
EV / EBITDA9.79
EV / EBIT9.79

Financial Position

As of September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 0.91, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.63, indicating elevated leverage, while an interest coverage ratio of 48.44 demonstrates strong ability to service its debt obligations.

Current Ratio0.91
Quick Ratio0.46
Debt / Equity68.63
Debt / EBITDA2.89
Interest Coverage48.44

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 698,623.48 in revenue per employee across its workforce of 41,141.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee698,623.48
Employee Count41,141.00

Taxes

CNY

Over the twelve months ended September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A recorded 556.03M in income tax expense. That works out to an effective tax rate of 26.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.12B, leaving 1.43B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax556.03M
Effective Tax Rate26.19

Stock Price Statistics

CNY

As of the close on November 17, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A's stock has gained approximately 14.65% over the past 52 weeks. The 50-day moving average sits at 18.93, while the 200-day moving average is 18.32.

52-Week Price Change14.65%
50-Day Moving Average18.93
200-Day Moving Average18.32

Income Statement

CNY

Over the twelve months ended September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A generated 28.74B in revenue and converted that into 1.43B in net income, yielding earnings per share of 1.38. EBITDA reached 2.12B, while operating income came in at 2.39B.

Revenue28.74B
Gross Profit9.90B
Operating Income2.39B
Pretax Income2.12B
Net Income1.43B
EBITDA2.12B
EBIT2.12B
Earnings Per Share (EPS)1.38

Balance Sheet

CNY

As of September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A holds 7.39B in cash and equivalents against 6.12B in total debt, resulting in a net debt position of -4.70B. Total book value stands at 7.60B, with working capital of -1.36B providing operational flexibility.

Cash & Cash Equivalents7.39B
Total Debt6.12B
Net Debt-4.70B
Equity (Book Value)7.60B
Book Value Per Share6.68
Working Capital-1.36B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-583.91M

Margins

Over the twelve months ended September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 34.45, reflecting its pricing power and cost economics. The operating margin of 8.32 and net profit margin of 4.96 provide insight into operational efficiency.

Gross Margin34.45
Operating Margin8.32
Pretax Margin7.39
Profit Margin4.96
EBITDA Margin7.38

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.86 per share. The dividend payout ratio of 57.23 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 10.88, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to DaShenLin Pharmaceutical Group Co., Ltd. Class A shareholders.

Dividend Per Share0.86
Payout Ratio57.23
Shareholder Yield10.88

Stock Splits

DaShenLin Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on June 9, 2023 with a 5:6 split ratio.

Last Split Date6/9/2023
Split Ratio5:6

Scores

As of September 30, 2026, DaShenLin Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 2.54, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.54